These findings suggest that DUB3 leads to drug resistance to BET inhibitors by stabilizing the BRD4 protein, suggesting that DUB3 is a feasible therapeutic target for overcoming the drug resistance of BET inhibitors in prostate cancer [73]. The gene discussed is DNER; the disease is Familial prostate cancer.